SOLTI-1710 PROMETEO II: Palbociclib in combination with letrozole in patients with hormone receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)
No Thumbnail Available
Identifiers
Date
2020-05-01
Authors
Ciruelos, E. M.
Gonzalez-Farre, X.
Perello, A.
Alba, E.
Palacios-Ozores, P.
Salvador-Bofil, J.
Merino, M.
Villagrasa, P.
Celiz, P.
Pascual, T.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
